Physician profile
John B Coll
NPI 1265439582
$530.10
in general payments reported to CMS, 2019-2025
13 companies · $100 in 2025
The $100 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $55.20 · 2020: $29.82 · 2021: $42.72 · 2022: $111 · 2023: $113 · 2024: $77.55 · 2025: $100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $291.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $291.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $122.47 | 2022-2023 | Tysabri, Vumerity |
| Abbvie INC. | $109.16 | 2021-2025 | |
| Allergan, INC. | $52.94 | 2019-2020 | |
| Life Molecular Imaging Ltd | $48.22 | 2025 | Neuraceq |
| Pfizer INC. | $37.99 | 2023-2024 | |
| Amneal Pharmaceuticals LLC | $28.03 | 2023 | Rytary |
| Insightec,INC | $27.49 | 2025 | Exablate |
| Lilly USA, LLC | $19.65 | 2021 | |
| Abbott Laboratories | $19.16 | 2023 | Penta |
| Acadia Pharmaceuticals INC | $17.11 | 2023 | Nuplazid |
| Emd Serono, INC. | $16.47 | 2019 | |
| Celgene Corporation | $15.80 | 2022 | |
| Resmed Corp | $15.61 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Coll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.